RhumbLine Advisers’s Capricor Therapeutics CAPR Stock Holding History

RhumbLine Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Buy	67,881 +15,798	+30%	+$479K	﹤0.01%	2053
2026 Q1	$1.58M	Buy	52,083 +5,106	+11%	+$136K	﹤0.01%	1977
2025 Q4	$1.36M	Sell	46,977 -3,902	-8%	-$51K	﹤0.01%	2070
2025 Q3	$367K	Sell	50,879 -2,571	-5%	-$18.9K	﹤0.01%	2883
2025 Q2	$531K	Buy	53,450 +3,636	+7%	+$38.4K	﹤0.01%	2653
2025 Q1	$473K	Buy	49,814 +3,731	+8%	+$51.8K	﹤0.01%	2613
2024 Q4	$636K	Buy	46,083 +14,169	+44%	+$248K	﹤0.01%	2514
2024 Q3	$485K	Buy	31,914 +1,028	+3%	+$5.08K	﹤0.01%	2714
2024 Q2	$147K	Buy	+30,886	New	+$172K	﹤0.01%	3386

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RhumbLine Advisers's CAPR Position: Q2 2026 in Review

RhumbLine Advisers increased its Capricor Therapeutics (CAPR) stake by 30% in Q2 2026, buying an estimated $479K and bringing the position to 67,881 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

RhumbLine Advisers first reported a position in CAPR in Q2 2024 and has held it in 9 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

RhumbLine Advisers held 67,881 shares of Capricor Therapeutics worth $1.63M as of Q2 2026.
RhumbLine Advisers bought 15,798 Capricor Therapeutics shares in Q2 2026, an estimated $479K.
Capricor Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2053 holding.
RhumbLine Advisers first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 9 quarters since.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.